Enzyl 160mg Tablet contains Enzalutamide, a nonsteroidal antiandrogen agent used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide acts by inhibiting androgen receptor signaling, thereby preventing the growth and proliferation of prostate cancer cells dependent on androgens. This medication is indicated for patients who have progressed despite androgen deprivation therapy, offering improved overall survival and delayed disease progression. Enzalutamide demonstrates high affinity for the androgen receptor, blocking its nuclear translocation, DNA binding, and coactivator recruitment, which collectively suppress tumor growth. The recommended dosage is 160 mg orally once daily, with or without food, and treatment should continue until disease progression or unacceptable toxicity occurs. Common adverse effects include fatigue, hypertension, hot flashes, headache, and musculoskeletal pain; serious but less frequent risks involve seizures and cardiovascular events, necessitating careful patient monitoring. Enzyl 160mg Tablet should be used cautiously in patients with a history of seizures or cardiovascular disorders. It is contraindicated in patients with hypersensitivity to Enzalutamide or any excipients. Drug interactions may occur due to CYP2C8 and CYP3A4 metabolism pathways; thus, concomitant use with strong inducers or inhibitors should be managed appropriately. Enzyl 160mg Tablet represents a significant advancement in prostate cancer therapy, improving patient outcomes in advanced disease stages.